ERBB2 and prostate carcinoma: Pathway analysis of the differentially enriched HER2+ EV miRNAs (FDR-corrected Wald test p < 0.05) revealed a strong association with various cancers and cancer-associated pathways, including FoxO and p53 signaling, as well as prostate cancer (Fig. 3G).